Identifying T-Cell Receptors to Improve Cancer Immunotherapy
Official title: Novel Approach to High-Throughput Identification and Characterization of Neoantigen-Specific T-Cell Receptors to Guide Immunotherapy Development.
Funded at Flexomics LLC · NIH-10652632 · Data updated 2026-11-12
This study is working on a new way to find and understand special immune cells that can target unique markers on cancer cells, with the hope of creating better and more personalized treatments for cancer patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Flexomics LLC NIH-funded |
| Lab location | 1 site (Waltham, United States) |
| Project start | June 15, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $846,678 |
| NIH project number | 5R44CA250673-03 |
| Project ID | NIH-10652632 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients whose tumors have unique neoantigens that are not currently targeted by existing therapies.
✕Less likely to help
Patients with tumors that do not express neoantigens or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research focuses on developing a new platform to identify and characterize T-cell receptors (TCRs) that specifically target neoantigens in cancer cells. By utilizing advanced techniques such as live cell analysis and single-cell genomics, the project aims to enhance the effectiveness of immunotherapy for cancer patients. The goal is to create a high-throughput method that can discover a wider range of TCRs, potentially providing more personalized treatment options for patients with various types of tumors. This innovative approach seeks to address the limitations of current therapies that often overlook less common mutations.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized immunotherapy options for cancer patients, improving treatment outcomes.
How similar studies have gone: Other research has shown promise in using similar high-throughput methods to identify TCRs, indicating that this approach could be effective.
Where this research is happening
-
Flexomics LLC
Waltham, United States Active
Researchers
- Principal investigator: Soumillon, Magali — Flexomics LLC
- Study coordinator: Soumillon, Magali
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.